ATAI Life Sciences

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Glenn Short, PhD, Vice President of Early Development, at ATAI Life Sciences (NASDAQ: ATAI) was a guest speaker at Benzinga’s Psychedelic Capital...

atai Life Sciences N.V. (NASDAQ: ATAI) has announced its financial results for the fourth quarter and full year ended December 31, 2021. 2021 Financial Results Highlights included:  Positive Phase 2b data with COMP360 from a ground-breaking treatment-resistant depression (TRD) trial, highly...

The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.   Collaboration with the National Institute...

Venture capitalist and businessman Stephen Jurvetson is joining an expanding group of prominent investors who are backing research into psychedelic ventures. Last week, Jurvetson spoke at the New York City conference “Horizons: Perspectives on Psychedelics” on the...

Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ: ATAI), a Peter Thiel-backed psychedelic startup that currently has 10 psychedelic programs in the works, has upped its stake in Compass Pathways (NASDAQ: CMPS), a drug developer looking to accelerate patient access to psilocybin...

Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O’Leary and Peter Thiel recognizing the potential in the psych drug industry.  Psychedelic drugs, such as psilocybin mushrooms and LSD, were once seen merely as a way for college...

Co-written by Andrew Ward and Natan Ponieman The race is continually heating up in the psychedelics space. An array of companies, educational institutions and investors have already obtained patents on formulations, processes, compounds and other aspects of psychedelics treatment. The race has...